As some adopt a wait-and-see attitude to the company's new multiple sclerosis drug Tysabri (natalizumab, formerly Antegren), Biogen Idec Inc. reported satisfying fourth-quarter 2004 earnings and offered guidance for the coming year near the top end of consensus estimates. (BioWorld Today) Read More